Pfizer Inc. with ticker code (PFE) now have 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 70.73 and 30.18 calculating the average target price we see $38.67. Given that the stocks previous close was at $30.43 and the analysts are correct then we can expect a percentage increase in value of 27.1%. It’s also worth noting that there is a 50 day moving average of $33.86 while the 200 day moving average is $38.26. The company has a market capitalization of 173.50B. The stock price for the company is currently 30.73 USD
The potential market cap would be $220,481,713,850 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 8.17, revenue per share of 13.86 and a 7.63% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
